By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Enterprise Replace First Website Activated for Section 3 OVATION 3 Trial of IMNN-001 in Ovarian Most cancers On Might 8, 2025, Imunon, Inc. (NASDAQ:IMNN) introduced that the primary trial web site for the Section 3 OVATION 3 trial has been activated and is able … Read more
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Enterprise Replace Replace on IMNN-101 Imunon, Inc. (NASDAQ:IMNN) is growing IMNN-101, which is a COVID-19 seasonal vaccine booster based mostly on the corporate’s PlaCCine know-how. It’s a DNA vaccine that addresses plenty of limitations of present vaccines, together with the sturdiness of antigen expression, … Read more
By David Bautz, PhD NASDAQ:CRVO READ THE FULL CRVO RESEARCH REPORT Enterprise Replace Biomarker Knowledge Introduced at AD/PD 2024 On March 5, 2024, CervoMed Inc. (NASDAQ:CRVO) introduced the presentation of biomarker knowledge from the AscenD-LB Part 2a trial of neflamapimod in sufferers with dementia with Lewy our bodies (DLB) was featured in a poster presentation … Read more
